VivoSeq
Other

Low Bone Mineral Density

0

Pipeline Programs↗

0

Active Trials↗

5

Companies Involved↗

Low Bone Mineral Density is an early-stage landscape with 0 programs across 5 companies. The most active players are Amgen, Eli Lilly, Deltanoid Pharmaceuticals.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

88/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Amgen logo

Amgen

0 programs

PreclinicalEli Lilly logo

Eli Lilly

0 programs

PreclinicalD

Deltanoid Pharmaceuticals

0 programs

PreclinicalUltragenyx logo

Ultragenyx

0 programs

PreclinicalNovartis logo

Novartis

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

16

clinical trials

Completed14 · 88%
Withdrawn1 · 6%
Terminated1 · 6%

Clinical Trials

Trial Activity

16 trials

Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density
Completed·Amgen logoAmgen·Phase 2·NCT00896532·419 enrolled
A Multicenter, Randomized Placebo Controlled Pilot MicroCT Study to Estimate the Effect of Treatment With Denosumab (AMG 162) and Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density
Completed·Amgen logoAmgen·Phase 2·NCT00293813·247 enrolled
A Randomized, Double-Blind Study to Compare the Efficacy of Treatment With Denosumab Versus Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density.
Completed·Amgen logoAmgen·Phase 3·NCT00330460·1,189 enrolled
A Study of LY2541546 in Women With Low Bone Mineral Density
Completed·Eli Lilly logoEli Lilly·Phase 2·NCT01144377·154 enrolled
Risedronate Therapy in the Treatment of Low Bone Mineral Density in Crohn's Disease
Completed·UUniversity of Alberta·Phase 4·NCT01215890
An Open-label, Single-arm Extension Study to Evaluate the Long-term Safety of Denosumab Administration in Postmenopausal Women With Low Bone Mineral Density
Completed·Amgen logoAmgen·Phase 3·NCT00325468·200 enrolled
An Ascending Multiple Dose Study Evaluating AMG 167 in Healthy Men and Postmenopausal Women With Low Bone Mineral Density
Completed·Amgen logoAmgen·Phase 1·NCT01101048·74 enrolled
Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density
Completed·Amgen logoAmgen·Phase 2·NCT00043186·412 enrolled
A Multi-Center, Randomized, Open-Label Study to Assess the Immunogenicity and Safety of Denosumab in Pre-filled Syringe Compared to Vial in Subjects With Low Bone Mineral Density
Completed·Amgen logoAmgen·Phase 3·NCT00515463·311 enrolled
Switch From Tenofovir to Raltegravir for Low Bone Mineral Density
Completed·SSt Vincent's Hospital, Sydney·Phase 4·NCT00939874·52 enrolled
Phase 2 Safety and Efficacy Study of a Vitamin D Compound (DP001) in Postmenopausal Women With Low Bone Mineral Density
Completed·DDeltanoid Pharmaceuticals·Phase 2·NCT00715676·157 enrolled
Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Post Menopausal Women With Low Bone Mineral Density
Completed·Ultragenyx logoUltragenyx·Phase 2·NCT01406548·44 enrolled
Effects of Zoledronic Acid and Raloxifene on Bone Turnover Markers in Postmenopausal Women With Low Bone Mineral Density
Completed·Novartis logoNovartis·Phase 4·NCT00431444·110 enrolled
Multicentre Study To Assess Changes In Bone Mineral Density Of The Switch From Protease Inhibitors To Dolutegravir In HIV-1-Infected Subjects With Low Bone Mineral Density
Completed·FFundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia·Phase 3·NCT01966822·75 enrolled
The Effects of Ibandronate or Teriparatide Therapy on Bone Histology and Biochemical Indices in Patients on Hemodialysis With Low Bone Mineral Density
Terminated·PPapageorgiou General Hospital·Phase 4·NCT00446589·19 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)